Litigation Details for Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private Limited (D. Del. 2022)
✉ Email this page to a colleague
Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private Limited (D. Del. 2022)
| Docket | ⤷ Start Trial | Date Filed | 2022-09-16 |
| Court | District Court, D. Delaware | Date Terminated | 2024-03-06 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Patents | 10,047,117; 10,052,337; 10,174,073; 10,751,349; 10,758,549; 9,238,673; RE48,286 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private Limited
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private Limited (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-09-16 | External link to document | |||
| 2022-09-16 | 1 | Complaint | expiration of U.S. Patent Nos. 9,238,673 (filed June 17, 2013) (“the ’673 Patent”); 10,047,117 (filed Nov. …Paragraph IV Certification of U.S. Patent Nos. 9,238,673; 10,047,117; 10,052,337; 10,174,073; 10,751,349… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…20, 2015) (“the ’117 Patent”); 10,052,337 (filed Apr. 26, 2016) (“the ’337 Patent”); 10,174,073 (filed…25, 2017) (“the ’073 Patent”); 10,751,349 (filed Jan. 15, 2019) (“the ʼ349 Patent”); and 10,758,549 (filed | External link to document |
| 2022-09-16 | 4 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,238,673 B2 ;10,047,117 B2 ;10,052,…2022 6 March 2024 1:22-cv-01215 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
